Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 61.540
Filter
1.
BMC Oral Health ; 24(1): 1165, 2024 Oct 01.
Article in English | MEDLINE | ID: mdl-39354469

ABSTRACT

BACKGROUND: Local anaesthesia in dental procedures is generally safe, although the occurrence of transient bradycardia (TB) has occasionally been reported. TB is often associated with two reflexes, the trigeminal cardiac reflex (TCR) and the vasovagal reflex (VVR) and is characterised by a rapid decrease in heart rate (HR) and blood pressure (BP). The prevalence of TCR is considered low, and its predictors have not been thoroughly investigated, although an association with the gag reflex has been suggested in recent years. METHODS: This prospective study assessed TB occurrence during local anaesthesia and its potential associated factors. A comprehensive questionnaire was used to categorise discomforts during dental treatment, and various anxiety scales were used to measure patients' anxiety levels. We investigated HR variability during local anaesthesia administration under sedation and the association between the incidence of TB and gag reflex. Subsequently, logistic regression analysis was performed to assess factors associated with TB occurrence. RESULTS: The prospective analysis included 188 patients of 234 initial patients. The analysis revealed a high TB incidence rate of 41% during local anaesthesia administration under sedation. No severe hypotensive events occurred, indicating a relatively benign nature of TB during local anaesthesia. TB occurrence was significantly higher in the group of patients with the gag reflex. Further analysis revealed that both gag reflex and trait anxiety were significantly associated with TB occurrence, whereas dental phobia did not directly correlate with TB. CONCLUSION: This study highlights the prominent occurrence of TB during local anaesthesia in dental treatment, which is primarily attributed to TCR activation. The identification of gag reflex and trait anxiety as independent factors associated with TB development may pave the way for TB prevention measures. Further research is required to clarify the mechanisms of TCR and perform safer dental procedures under sedation. Future studies should also aim to elucidate the precise mechanisms underlying TB during local anaesthesia through direct measurements of neural activity. A better understanding of TB in dentistry is crucial for improving patient safety and optimising dental practice protocols.


Subject(s)
Anesthesia, Dental , Anesthesia, Local , Bradycardia , Humans , Prospective Studies , Bradycardia/chemically induced , Female , Male , Anesthesia, Local/adverse effects , Anesthesia, Local/methods , Adult , Anesthesia, Dental/adverse effects , Anesthesia, Dental/methods , Middle Aged , Dental Anxiety , Gagging , Aged , Heart Rate/drug effects , Conscious Sedation/adverse effects , Conscious Sedation/methods , Adolescent
2.
Sci Rep ; 14(1): 23096, 2024 10 04.
Article in English | MEDLINE | ID: mdl-39367115

ABSTRACT

Epinephrine is the only recommended vasopressor during neonatal cardiopulmonary resuscitation. However, there are concerns about the potential adverse effects of epinephrine, which might hamper efficacy during cardiopulmonary resuscitation. An alternative might be vasopressin, which has a preferable adverse effect profile, however, its optimal dose and route of administration is unknown. We aimed to compare the pharmacodynamics and pharmacokinetics of various vasopressin doses administered via intravenous (IV), intraosseous (IO), endotracheal (ETT), and intranasal (IN) routes in healthy neonatal piglets. Forty-four post-transitional piglets (1-3 days of age) were anesthetized, intubated via a tracheostomy, and randomized to receive vasopressin via intravenous (control), IO, ETT, or IN route. Heart rate (HR), arterial blood pressure, carotid blood flow, and cardiac function (e.g., stroke volume, ejection fraction) were continuously recorded throughout the experiment. Blood was collected prior to drug administration and throughout the observation period for pharmacodynamics and pharmacokinetic analysis. Significant changes in hemodynamic parameters were observed following IO administration of vasopressin while pharmacokinetic parameters were not different between IV and IO vasopressin. Administration of vasopressin via ETT or IN did not change hemodynamic parameters and had significantly lower maximum plasma concentrations and systemic absorption compared to piglets administered IV vasopressin (p < 0.05). The IV and IO routes appear the most effective for vasopressin administration in neonatal piglets, while the ETT and IN routes appear unsuitable for vasopressin administration.


Subject(s)
Animals, Newborn , Vasopressins , Animals , Vasopressins/pharmacokinetics , Vasopressins/administration & dosage , Swine , Vasoconstrictor Agents/pharmacokinetics , Vasoconstrictor Agents/administration & dosage , Vasoconstrictor Agents/pharmacology , Hemodynamics/drug effects , Heart Rate/drug effects , Drug Administration Routes , Blood Pressure/drug effects , Cardiopulmonary Resuscitation , Administration, Intravenous , Dose-Response Relationship, Drug
3.
Part Fibre Toxicol ; 21(1): 42, 2024 Oct 08.
Article in English | MEDLINE | ID: mdl-39379984

ABSTRACT

BACKGROUND: Subway systems are becoming increasingly common worldwide transporting large populations in major cities. PM2.5 concentrations have been demonstrated to be exceptionally high when underground, however. Studies on the impact of subway PM exposure on cardiopulmonary health in the United States are limited. METHODS: Healthy volunteers in New York City were exposed to a 2-h visit on the 9th Street Station platform on the Port Authority Trans-Hudson train system. Blood pressure, heart rate variability (HRV), spirometry, and forced impulse oscillometry were measured, and urine, blood spot, and nasal swab biosamples were collected for cytokine analysis at the end of the 2-h exposure period. These endpoints were compared against individual control measurements collected after 2-h in a "clean" control space. In addition to paired comparisons, mixed effects models with subject as a random effect were employed to investigate the effect of the PM2.5 concentrations and visit type (i.e., subway vs. control). RESULTS: Mean PM2.5 concentrations on the platform and during the control visit were 293.6 ± 65.7 (SD) and 4.6 ± 1.9 µg/m3, respectively. There was no change in any of the health metrics, but there was a non-significant trend for SDNN to be lower after subway exposure compared to control exposure. Total symptomatic scores did increase post-subway exposure compared to reported values prior to exposure or after the control visit. No significant changes in cytokine concentrations in any specimen type were observed. Mixed-effects models mostly corroborated these paired comparisons. CONCLUSIONS: Acute exposures to PM on a subway platform do not cause measurable cardiopulmonary effects apart from reductions in HRV and increases in symptoms in healthy volunteers. These findings match other studies that found little to no changes in lung function and blood pressure after exposure in underground subway stations. Future work should still target potentially more vulnerable populations, such as individuals with asthma or those who spend increased time underground on the subway such as transit workers.


Subject(s)
Blood Pressure , Cytokines , Healthy Volunteers , Heart Rate , Particulate Matter , Humans , New York City , Particulate Matter/analysis , Pilot Projects , Male , Adult , Heart Rate/drug effects , Female , Blood Pressure/drug effects , Cytokines/blood , Air Pollutants/analysis , Inhalation Exposure/adverse effects , Inhalation Exposure/analysis , Particle Size , Middle Aged , Railroads , Young Adult , Lung/drug effects
4.
Nutrients ; 16(18)2024 Sep 22.
Article in English | MEDLINE | ID: mdl-39339805

ABSTRACT

Background/Objectives: Colostrum Bovinum (COL) is recognized for its unique composition and potential ergogenic and immunological benefits. Unlike mature milk, COL is rich in immunoglobulins, lactoferrin, and various growth factors, making it one of the most potent natural immune stimulants. The purpose of this study was to evaluate the effects of 12-weeks of COL supplementation on swimming-specific performance (SSP) and exercise adaptations in endurance-trained male athletes. Methods: Twenty-eight male triathletes and swimmers (age: 31.1 ± 10.2 years; body mass: 81.9 ± 9.0 kg; height: 1.82 ± 0.06 m) participated in a randomized, double-blind, placebo (PLA)-controlled crossover study and received 25 g∙day-1 of COL or PLA for 12 weeks. The study assessed the effects of COL on SSP (8 × 100 m performed at various intensities) and exercise adaptations [heart rate (HR) and blood lactate concentrations ([La-])]. Four main study visits were conducted-before and after COL (COLPRE and COLPOST) and PLA (PLAPRE and PLAPOST) supplementation. Results: COL had no significant effect on SSP. Still, the total time of the SSP test was about ~3.04 s shorter after COL supplementation, and ~7.13 s longer after PLA supplementation. Neither COL nor PLA supplementation affected HR during the SSP test. Post-exercise blood [La-] was significantly reduced after both COL and PLA supplementation. The analysis of SSP results in the consecutive study visits revealed possible existence of the practice effect. Conclusions: Colostrum Bovinum and high-quality milk protein (PLA) seem to be comparably effective in evoking exercise adaptation in endurance-trained male athletes. Long-term crossover supplementation protocols in athletes must consider the impact of possible practice effect when interpreting the outcomes related to exercise performance, but not biochemical or physiological markers of exercise adaptation.


Subject(s)
Athletic Performance , Colostrum , Cross-Over Studies , Dietary Supplements , Physical Endurance , Swimming , Humans , Male , Swimming/physiology , Adult , Double-Blind Method , Athletic Performance/physiology , Physical Endurance/drug effects , Physical Endurance/physiology , Young Adult , Animals , Lactic Acid/blood , Heart Rate/drug effects , Athletes , Adaptation, Physiological
5.
Toxins (Basel) ; 16(9)2024 Aug 28.
Article in English | MEDLINE | ID: mdl-39330835

ABSTRACT

Ophidism is a public health problem in tropical countries, occurring predominantly in rural areas. In Colombia, among the species responsible for snakebite envenomation, inflicting high mortality, is the Chocoan bushmaster, Lachesis acrochorda, better known locally by the names "verrugosa (warty)" and "pudridora (rot-causing)". In this research, the cardiotoxic effect of the venom of L. acrochorda in male Wistar rats weighing 230 ± 20 g was evaluated. A statistical design of randomized blocks was implemented with three treated groups, injected with lyophilized venom (doses of 3.22 µg/g, 6.43 µg/g, 12.86 µg/g), and a control group injected with 0.9% saline solution. Electrocardiographic (ECG) recordings were taken from the anesthetized animals, revealing an increase in the amplitude of the P and T waves and an increase in the duration of the QT intervals in the electrocardiographic recordings. These increases were not observed in the control biomodels. In the analysis of the CK and CK-MB enzyme levels, increases were also observed in the levels of cardiac isoenzymes in the injected animals, but none in the control animals. The histopathological analyses carried out reveal that the injected animals showed effects such as interfibrillar and perivascular edema, cellular shortening of the cardiomyocytes, foci with tissue destructuring, and necrosis with contraction bands. In conclusion, the venom of the Lachesis acrochorda snake increases the P and T waves and the QT interval and increases the CK and CK-MB enzymes in the blood. Additionally, it causes interfibrillar and perivascular edema in the cardiac tissue, cardiocytolysis, and contraction bands.


Subject(s)
Rats, Wistar , Viperidae , Animals , Male , Electrocardiography , Heart/drug effects , Rats , Creatine Kinase, MB Form/blood , Viper Venoms/toxicity , Creatine Kinase/blood , Myocardium/pathology , Heart Rate/drug effects
6.
Pak J Pharm Sci ; 37(3): 639-649, 2024 May.
Article in English | MEDLINE | ID: mdl-39340855

ABSTRACT

Beta blockers (BB) and calcium channel blockers (CCB) are highly effective to suppress angina attacks. Current observational study is designed to investigate the effectiveness of BB, CCB and its combination in angina patients. Angina patients from different tertiary care hospital cardiology OPDs were recruited from June 2022 to June 2023. Patient's history and suspected adverse drug effects (ADE) observed by manual chart review. Results showed baseline demographics and comorbidities were similar. Medication assessment revealed that most patients were on CCB (54.4%) and BB (36.36%) than combination (9.8%). Compared with BB, CCB and combination drugs taking patients represented stable heart rate and blood pressure (P<0.05). There were insignificant differences were observed in electrolytes and lipid profile in each groups. In addition, the Seattle questionnaire for angina (SQA) showed improved symptoms in 83 patients out of 110 (P<0.05). Further ADE were observed by using Naranjo scale that represented BB taking patients were found to have more ADRs than CCB and combination therapy. In conclusion, patients using BB, CCB or a combination of CCB+BB had improved angina symptoms and represented same efficacy however CCB exhibited lesser number of ADRs that shows CCB is more effective than BB in prolong use of angina control.


Subject(s)
Adrenergic beta-Antagonists , Angina Pectoris , Calcium Channel Blockers , Humans , Calcium Channel Blockers/adverse effects , Calcium Channel Blockers/therapeutic use , Female , Male , Middle Aged , Angina Pectoris/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Adrenergic beta-Antagonists/adverse effects , Aged , Treatment Outcome , Drug Therapy, Combination , Heart Rate/drug effects , Blood Pressure/drug effects
7.
BMC Anesthesiol ; 24(1): 326, 2024 Sep 12.
Article in English | MEDLINE | ID: mdl-39266951

ABSTRACT

BACKGROUND: Sepsis is associated with a high incidence and mortality and poses a significant challenge to the treatment. Although esmolol has shown promise in sepsis treatment, its efficacy and safety remain contentious. This meta-analysis aims to clarify the role of esmolol in sepsis management. METHODS: PubMed, Embase, Web of Science, Cochrane library, clinicaltrials.gov and the Chinese Clinical Trial Registry were searched and references of relevant reviews and meta-analysis were also screened for appropriate studies. Keywords and free words of 'sepsis', 'esmolol' and 'randomized controlled trials' were used for search. Meta-analysis was performed using RevMan 5.3 software. RESULTS: Fifteen studies involving 1100 patients were included. Compared with the control group, patients receiving esmolol exhibited significantly decreased 28-day mortality (RR, 0.69; 95% CI, 0.60 to 0.81; P < 0.0001), heart rate (HR) (SMD, -1.15; 95% CI, -1.34 to -0.96; P < 0.0001), cardiac troponin I levels (cTnI) (SMD, -0.88; 95% CI, -1.13 to -0.64; P < 0.0001), length of intensive care unit (ICU) stay (SMD, -0.46; 95% CI, -0.62 to -0.3; P < 0.0001) and duration of mechanical ventilation (SMD, -0.28; 95% CI, -0.48 to -0.09; P = 0.004) and significantly increased central venous oxygen saturation (ScvO2) (SMD, 0.66; 95% CI, 0.44 to 0.88; P < 0.0001).While, esmolol had no significant influence on norepinephrine dosage (SMD, 0.08; 95% CI, -0.13 to 0.29; P = 0.46), mean arterial pressure (MAP) (SMD, 0.17; 95% CI, -0.07 to 0.4; P = 0.16), central venous pressure (CVP) (SMD, 0.16; 95% CI, -0.04 to 0.35; P = 0.11) and left ventricular ejection fraction (LVEF) (SMD, 0.21; 95% CI, -2.9 to 0.7; P = 0.41). CONCLUSION: Esmolol reduces 28-day mortality, length of ICU stay and duration of mechanical ventilation in sepsis patients. Furthermore, esmolol improves oxygen metabolism, mitigates myocardial injury and decreases heart rate without significantly affecting hemodynamic parameters. TRIAL REGISTRATION: This study was registered on the PROSPERO website (registration number: CRD42023484884).


Subject(s)
Adrenergic beta-1 Receptor Antagonists , Propanolamines , Sepsis , Humans , Adrenergic beta-1 Receptor Antagonists/therapeutic use , Heart Rate/drug effects , Heart Rate/physiology , Length of Stay , Propanolamines/therapeutic use , Randomized Controlled Trials as Topic/methods , Sepsis/drug therapy
8.
J Hazard Mater ; 479: 135690, 2024 Nov 05.
Article in English | MEDLINE | ID: mdl-39255669

ABSTRACT

ß-ionone is a volatile metabolite of Microcystis aeruginosa that is toxic to aquatic organisms. Using Daphnia sinensis as model, our present study found that ß-ionone could significantly reduce heart rate and feeding rate, and induce intestinal emptying. Transcriptomic analysis showed that ß-ionone could significantly inhibit the expression of acetylcholinesterase (AchE) mRNA, while metabolomics further revealed that ß-ionone could significantly increase the level of acetylcholine (Ach) in D. sinensis. These results indicated that ß-ionone might act as an AchE inhibitor, resulting in an increase in Ach levels. To test this hypothesis, both in vivo and in vitro experiments demonstrated that ß-ionone could significantly reduce AchE activity. Furthermore, the inhibitory effects of ß-ionone on heart rate and feeding rate could be blocked by the M-type Ach receptor (mAchR) blocker. These findings confirm that ß-ionone is a novel AchE inhibitor. ß-ionone could inhibit the activity of AchE, which in turn resulted in an increase of Ach in D. sinensis. Consequently, elevated levels of Ach could suppress the heart rate and feeding rate of D. sinensis by activating the mAchR, while concurrently accelerating the rate of intestinal emptying by stimulating intestinal peristalsis, thereby obstructing the digestion of algae within the intestinal tract.


Subject(s)
Acetylcholinesterase , Cholinesterase Inhibitors , Daphnia , Norisoprenoids , Animals , Acetylcholinesterase/metabolism , Cholinesterase Inhibitors/toxicity , Cholinesterase Inhibitors/pharmacology , Daphnia/drug effects , Norisoprenoids/pharmacology , Heart Rate/drug effects , Feeding Behavior/drug effects , Acetylcholine/metabolism
9.
J Pharmacol Toxicol Methods ; 129: 107551, 2024.
Article in English | MEDLINE | ID: mdl-39245416

ABSTRACT

This paper introduces an efficient methodology for conducting rat anesthesia experiments, aimed at enhancing the quality of raw brain signals obtained. The proposed approach enables the acquisition of animal brain signals during experiments without the confounding influence of muscle noise. Initially, the use of alpha-chloralose (a-c) in conjunction with Isoflurane is introduced to induce anesthesia in rats. Subsequently, Dexdomitor is administered to prevent muscular movements during the collection of brain signals, further refining the signal quality. Experimental outcomes conclusively demonstrate that our anesthesia method produces cleaner raw signals and exhibits improved robustness during data acquisition, outperforming existing methods that rely solely on Isoflurane or the Ketamine-Xylazine combination. Notably, this improved performance is achieved with minimal alterations to vital physiological parameters, including body temperature, respiration, and heart rates. Moreover, the efficacy of a-c in maintaining anesthesia for up to 7 h stands in contrast to the shorter durations achievable with continuous Isoflurane administration or the 30-min window offered by Ketamine-Xylazine, highlighting the practical advantages of our proposed method. Finally, post-experiment observations confirmed that the animals gradually returned to normal behavior without any signs of distress or adverse effects, indicating that our method was both effective and safe.


Subject(s)
Brain , Isoflurane , Ketamine , Xylazine , Animals , Rats , Isoflurane/pharmacology , Isoflurane/administration & dosage , Brain/drug effects , Brain/physiology , Male , Xylazine/pharmacology , Ketamine/pharmacology , Ketamine/administration & dosage , Chloralose/pharmacology , Anesthesia/methods , Anesthetics, Inhalation/pharmacology , Anesthetics, Inhalation/administration & dosage , Rats, Sprague-Dawley , Anesthetics/pharmacology , Anesthetics/administration & dosage , Body Temperature/drug effects , Body Temperature/physiology , Heart Rate/drug effects , Dexmedetomidine/pharmacology , Electroencephalography/methods , Electroencephalography/drug effects
10.
Sci Rep ; 14(1): 21434, 2024 09 13.
Article in English | MEDLINE | ID: mdl-39271709

ABSTRACT

Systemic arterial hypertension is accompanied by autonomic impairments that, if not contained, promotes cardiac functional and morphological damages. Pyridostigmine bromide (PYR) treatment results in positive effects on autonomic control and beneficial cardiac remodeling. These findings were also observed after aerobic physical training (APT). However, little is known about PYR effects on left ventricular contractility, mainly when it is combined with APT. We aimed to investigate the effects of chronic acetylcholinesterase inhibition on cardiac autonomic tone balance, coronary bed reactivity, and left ventricular contractility in spontaneously hypertensive rats (SHR) submitted to APT. Male SHR (18 weeks) were divided into two groups (N = 16): untrained and submitted to APT for 14 weeks (18th to 32nd week). Half of each group was treated with PYR (15 mg/kg/day) for two weeks (31st to 32nd week). The experimental protocol consisted of recording hemodynamic parameters, double autonomic blockade with atropine and propranolol, and assessment of coronary bed reactivity and ventricular contractility in isolated hearts using the Langendorff technique. PYR and APT reduced blood pressure, heart rate, and sympathetic influence on the heart. The Langendorff technique showed that APT increased coronary perfusion pressure and left ventricle contractility in response to coronary flow and ß-agonist administration. However, treatment with PYR annulled the effects of APT. In conclusion, although chronic treatment with PYR reduces cardiac sympathetic tonic influence, it does not favor coronary bed reactivity and cardiac contractility gains. PYR treatment in the trained SHR group nullified the coronary vascular reactivity and cardiac contractility gains.


Subject(s)
Cholinesterase Inhibitors , Hypertension , Myocardial Contraction , Physical Conditioning, Animal , Pyridostigmine Bromide , Rats, Inbred SHR , Animals , Cholinesterase Inhibitors/pharmacology , Male , Rats , Myocardial Contraction/drug effects , Hypertension/drug therapy , Hypertension/physiopathology , Pyridostigmine Bromide/pharmacology , Blood Pressure/drug effects , Heart Rate/drug effects , Hemodynamics/drug effects , Coronary Vessels/drug effects , Coronary Vessels/physiopathology , Ventricular Function, Left/drug effects , Acetylcholinesterase/metabolism
11.
PLoS One ; 19(9): e0309404, 2024.
Article in English | MEDLINE | ID: mdl-39226288

ABSTRACT

Scientists and coaches seek effective ergogenic aids for performance improvement. Cyclists commonly use ß-Alanine, which may enhance post-exercise recovery and physical performance. High-dose ß-Alanine supplementation's impact on World Tour cyclists during a 7-day camp remains unstudied. This study aimed to analyse the effect of a high dose of ß-alanine in World Tour cyclist during a 7-day camp. A double-blinded, randomised controlled trial was conducted. 11 cyclists were included in the final analysis: ß-alanine supplementation (n = 5; VO2max: 67.6±1.6 ml/kg/min) and a placebo group (n = 6; VO2max: 68.0±2.4 ml/kg/min). The duration of the supplementation protocol was seven days with four daily intakes. The subjects commenced supplementation after the physical tests (immediately following the snack) and consumed the final intake after breakfast on the day of the final test (a total of 7 days and 3 additional doses, 31 servings in total; 5g per dosage; 155g the total cumulative amount). Before and after seven days of supplementation, the cyclists performed an uphill time trial. Blood lactate, heart rate and rating of perceived exertion were measured during test. ß-alanine supplementation improved the relative mean power attained during the time-trial compared with the control group (Z = -2.008; p = 0.045; Δ = 0.060), as well as the time needed to complete this trial (Z = -2.373; p = 0.018). As for physiological and metabolic variables, no significant change was found. In conclusion, the present study supports the effectiveness of one-week high dose of ß-alanine during a cycling training in World Tour cyclists to improve their uphill time-trial performance. In addition, it is important to highlight the potential role of ß-alanine in improving recovery power. This aspect is particularly relevant in the context of a training camp, where fatigue levels can increase alongside training intensity. Trial registration: This study was registered in ClinicalTrials.gov: (identifier: NCT04427319).


Subject(s)
Athletic Performance , Bicycling , Dietary Supplements , beta-Alanine , Humans , beta-Alanine/administration & dosage , beta-Alanine/pharmacology , Bicycling/physiology , Male , Athletic Performance/physiology , Adult , Double-Blind Method , Heart Rate/drug effects , Lactic Acid/blood , Young Adult , Female
12.
J Zoo Wildl Med ; 55(3): 704-712, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39255211

ABSTRACT

Combinations of a low dose of opioid, such as thiafentanil, and a high dose of medetomidine, are increasingly being used for immobilization of African ungulates. Both drugs can have undesirable cardiorespiratory effects. In this study we assessed whether vatinoxan, a peripherally acting alpha2-adrenergic receptor antagonist, can be used to alleviate some of these effects without affecting the immobilization quality. Eight healthy, female, boma-confined blesbok (Damaliscus pygargus phillipsi), weighing a mean (SDtion) of 56.8 (4.4) kg, were immobilized twice in a randomized cross-over study with a 2-wk washout period using (1) 0.5 mg thiafentanil + 1.5 mg medetomidine (TM), (2) TM + vatinoxan: 0.5 mg thiafentanil + 1.5 mg medetomidine + 15 mg vatinoxan per milligram medetomidine (total of 22.5 mg, administered intramuscularly at 10 min post recumbency). Heart rate, respiratory rate, rectal temperature, oxygen saturation (SpO2), arterial blood pressure, and sedation scores from 1 to 5 (1 = limited effect; 5 = excessively deep) were measured every 5 min. Arterial blood gases (PaO2 and PaCO2) were measured at 10, 15, 25, and 35 min postrecumbency and the alveolar--arterial oxygen gradient (P[A-a]O2) was calculated. Induction times and immobilization quality did not differ between groups. The heart rate was significantly higher and the mean arterial pressure significantly lower in blesbok after receiving vatinoxan. All animals were hypoxemic and there were no significant differences in the respiratory rates, PaO2, PaCO2, SpO2, or P(A-a)O2 gradients at any time point. Although vatinoxan did not improve respiratory variables and blood oxygenation in these animals, the change in cardiovascular variables may suggest that it improves tissue perfusion, a positive outcome that requires further investigation.


Subject(s)
Cross-Over Studies , Fentanyl , Hypnotics and Sedatives , Immobilization , Medetomidine , Animals , Medetomidine/pharmacology , Medetomidine/administration & dosage , Female , Hypnotics and Sedatives/pharmacology , Hypnotics and Sedatives/administration & dosage , Fentanyl/pharmacology , Fentanyl/administration & dosage , Fentanyl/analogs & derivatives , Immobilization/veterinary , Heart Rate/drug effects , Quinolizines/pharmacology , Quinolizines/administration & dosage , Blood Pressure/drug effects , Boidae , Respiration/drug effects , Analgesics, Opioid/pharmacology , Analgesics, Opioid/administration & dosage
13.
PLoS One ; 19(9): e0310271, 2024.
Article in English | MEDLINE | ID: mdl-39255295

ABSTRACT

INTRODUCTION: Mental fatigue (MF) significantly affects both cognitive and physical performance. However, the precise mechanisms, particularly concerning neurotransmission, require further investigation. An implication of the role of dopamine (DA) and noradrenaline (NA) is stated, but empirical evidence for this theory still needs to be provided. To address this gap, we aim to investigate the role of brain neurotransmission in elucidating if, and how prolonged cognitive activity induces MF and its subsequent impact on cognitive performance. METHODS: This study (registration number: G095422N) will adopt a randomized cross-over design with sixteen healthy participants aged 18-35 years. The sessions include a familiarization, two experimental (DA: 20mg Methylphenidate; NA: 8mg Reboxetine) conditions, and one placebo (lactose tablet: 10mg) condition. A 60-minute individualized Stroop task will be used to investigate whether, and how the onset of MF changes under the influence of reuptake inhibitors. Attention and response inhibition will be assessed before and after the MF-inducing task using a Go/NoGo task. The integration of physiological (electroencephalography, heart rate), behavioral (attention, response inhibition), and subjective indicators (scales and questionnaires) will be used to detect the underlying mechanisms holistically. Data analysis will involve linear mixed models with significance at p<0.05. DISCUSSION: The integration of diverse techniques and analyses offers a comprehensive perspective on the onset and impact of MF, introducing a novel approach. Future research plans involve extending this protocol to explore the connection between brain neurotransmission and physical fatigue. This protocol will further advance our understanding of the complex interplay between the brain and fatigue.


Subject(s)
Brain , Cross-Over Studies , Mental Fatigue , Methylphenidate , Synaptic Transmission , Humans , Mental Fatigue/physiopathology , Adult , Adolescent , Young Adult , Brain/physiology , Brain/metabolism , Brain/drug effects , Synaptic Transmission/drug effects , Synaptic Transmission/physiology , Methylphenidate/pharmacology , Male , Female , Reboxetine , Cognition/physiology , Norepinephrine/metabolism , Heart Rate/drug effects , Heart Rate/physiology , Attention/physiology , Attention/drug effects , Electroencephalography , Dopamine/metabolism
14.
Clin Exp Pharmacol Physiol ; 51(10): e13915, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39227010

ABSTRACT

S-Limonene (s-Lim) is a monocyclic monoterpene found in a variety of plants and has been shown to present antioxidant and cardioprotective activity in experimental models of myocardial infarction. The aim of this study was to evaluate the potential mechanism by which s-Lim exerts its antiarrhythmic effect, focusing on the blockade of ß-adrenoceptor (ß-AR) and its effects on various in vivo and in vitro parameters, including electrocardiogram (ECG) measurements, left ventricular developed pressure (LVDP), the ß-adrenergic pathway, sarcomeric shortening and L-type calcium current (ICa,L). In isolated hearts, 10 µM of s-Lim did not alter the ECG profile or LVPD. s-Lim increased the heart rate corrected QT interval (QTc) (10.8%) at 50 µM and reduced heart rate at the concentrations of 30 (12.4%) and 50 µM (16.6%). s-Lim (10 µM) also inhibited the adrenergic response evoked by isoproterenol (ISO) (1 µM) reducing the increased of heart rate, LVDP and ECG changes. In ventricular cardiomyocyte, s-Lim antagonized the effect of dobutamine by preventing the increase of sarcomeric shortening, demonstrating a similar effect to atenolol (blocker ß1-AR). In vivo, s-Lim antagonized the effect of ISO (agonists ß1-AR), presenting a similar effect to propranolol (a non-selective blocker ß-AR). In ventricular cardiomyocyte, s-Lim did not alter the voltage dependence for ICa,L activation or the ICa,L density. In addition, s-Lim did not affect changes in the ECG effect mediated by 5 µM forskolin (an activator of adenylate cyclase). In an in vivo caffeine/ISO-induced arrhythmia model, s-Lim (1 mg/kg) presented antiarrhythmic action verified by a reduced arrhythmia score, heart rate, and occurrence of ventricular premature beats and inappropriate sinus tachycardia. These findings indicate that the antiarrhythmic activity of s-Lim is related to blockade of ß-AR in the heart.


Subject(s)
Anti-Arrhythmia Agents , Limonene , Rats, Wistar , Receptors, Adrenergic, beta , Signal Transduction , Animals , Rats , Anti-Arrhythmia Agents/pharmacology , Male , Receptors, Adrenergic, beta/metabolism , Limonene/pharmacology , Signal Transduction/drug effects , Terpenes/pharmacology , Heart/drug effects , Heart Rate/drug effects , Cyclohexenes/pharmacology , Arrhythmias, Cardiac/drug therapy , Arrhythmias, Cardiac/metabolism , Arrhythmias, Cardiac/chemically induced , Arrhythmias, Cardiac/physiopathology , Isoproterenol/pharmacology , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism
15.
Int J Med Mushrooms ; 26(11): 51-64, 2024.
Article in English | MEDLINE | ID: mdl-39241163

ABSTRACT

Psychological disparities impact physical activity and fitness in sedentary female college students by affecting cardiovascular efficiency. Ganoderma lucidum, vitality-enhancing herb alleviates health and rejuvenates the mind-body to improve endurance fitness. A double-blinded, randomized, placebo-controlled parallel design study was conducted to determine whether supplementation of G. lucidum in daily dosages of 500 mg (GL500mg group) and 1000 mg (GL1000mg group) improves psychophysiological health capabilities during the different phases of the experimental trial. Analysis for pre-experimental trial (day 0), experimental trial (day 15), and post-experimental trial (after day 30) on anthropometric, psychological, physiological, and physical fitness parameters were executed. Seventy-eight participants (n = 78, age 20.64 ± 3.21 years) were assigned randomly and equally divided (n = 26) to one of the three treatment groups for intragroup and intergroup comparisons. Significant differences in the post-experimental GL1000mg group for heart rate (HR), maximal oxygen consumption (VO2max), physical work capacity (PWC170), and right-hand grip strength (P < 0.05) compared with the placebo group were observed. GL1000mg-supplemented group also significantly improved (P < 0.05) HR, VO2max and PWC170 (P < 0.001) after pre- to post-trials. Experimental trial between placebo and GL1000mg group and post-experimental trial between the GL500mg and GL1000mg group showed significant changes in VO2max(P < 0.001) and PWC170 (P < 0.05). Anxiety, depression, vitality and positive well-being scores significantly improved, leading to improved psychological well-being after GL1000mg supplementation. GL1000mg supplementation for 30 days might act as a longevity-promoting tonic for endurance and strength performance by ameliorating stress to improve the overall psychophysiological health, vitality and quality of life for better cardiovascular efficacy.


Subject(s)
Dietary Supplements , Physical Fitness , Reishi , Stress, Psychological , Students , Humans , Female , Reishi/chemistry , Young Adult , Students/psychology , India , Double-Blind Method , Dietary Supplements/analysis , Stress, Psychological/drug therapy , Adult , Adolescent , Heart Rate/drug effects , Oxygen Consumption/drug effects , Hand Strength , Universities
16.
Transl Psychiatry ; 14(1): 357, 2024 Sep 04.
Article in English | MEDLINE | ID: mdl-39231959

ABSTRACT

The pharmacodynamic effects of lysergic acid diethylamide (LSD) are diverse and different in different individuals. Effects of other psychoactive substances have been shown to be critically influenced by non-pharmacological factors such as personality traits and mood states. The aim of this study was to determine pharmacological and psychological predictors of the LSD effects in healthy human subjects. This analysis is based on nine double-blind, placebo-controlled, cross-over studies with a total of 213 healthy subjects receiving between 25-200 µg LSD. The influence of sex, age, dose, body weight, pharmacogenetic, drug experience, personality, setting, and mood before drug intake on the peak autonomic and total subjective responses to LSD was investigated using multiple linear mixed effects models and Least Absolute Shrinkage and Selection Operator regression. Results were adjusted for LSD dose and corrected for multiple testing. LSD dose emerged as the most influential predictor, exhibiting a positive correlation with most response variables. Pre-drug mental states such as "Well-Being", "Emotional Excitability", and "Anxiety" were also important predictor for a range of subjective effects but also heart rate and body temperature. The trait "Openness to Experiences" was positively correlated with elevated ratings in "Oceanic Boundlessness" and mystical-type effects. Previous experiences with hallucinogens have been negatively associated with the overall altered state of consciousness and particularly with "Anxious Ego Dissolution". Acute anxiety negatively correlated with the genetically determined functionality of the Cytochrome 2D6 enzyme. In summary, besides the amount of drug consumed, non-pharmacological factors such as personal traits and current mood also significantly predicted the subjective drug experience. Sex and body weight were not significant factors in influencing the drug experience.


Subject(s)
Affect , Cross-Over Studies , Hallucinogens , Lysergic Acid Diethylamide , Humans , Lysergic Acid Diethylamide/pharmacology , Lysergic Acid Diethylamide/administration & dosage , Male , Female , Adult , Hallucinogens/administration & dosage , Hallucinogens/pharmacology , Double-Blind Method , Young Adult , Affect/drug effects , Healthy Volunteers , Heart Rate/drug effects , Personality , Middle Aged , Dose-Response Relationship, Drug , Adolescent
17.
BMC Res Notes ; 17(1): 246, 2024 Sep 03.
Article in English | MEDLINE | ID: mdl-39227898

ABSTRACT

The study aimed to investigate the effects of acute ingestion of saffron (SAF) on physiological (i.e., heart rate and blood lactate) and perceptual (i.e., ratings of perceived exertion [RPE] and feeling scale) measures in response to a repeated-sprint ability test (RSS) in healthy young males (N = 22; mean ± SD: age, 21.7 ± 1.24 yrs.). All participants completed two experimental trials with a one-week washout period using a double-blind, placebo-controlled, crossover design. In each session, the participants were randomly chosen to receive either a capsule of saffron (300 mg) (SAF session) or a capsule of lactose (PLB session) two hours before performing the RSS.No significant differences (p > 0.05) were found for heart rate, RPE, and feeling scale between the SAF or PLB sessions at pre- and post-RSS. There were no significant changes (p > 0.05) in peak time, total time, fatigue index, and blood lactate in either the SAF or PLB sessions. Acute SAF ingestion did not significantly improve RSS performance nor physiological and perceptual measures in active young males. Future trials should address the topic by using shortened/prolonged higher doses of SAF on biological, physical, physiological, and perceptual responses to acute and chronic exercise.


Subject(s)
Crocus , Cross-Over Studies , Heart Rate , Lactic Acid , Humans , Male , Young Adult , Heart Rate/drug effects , Heart Rate/physiology , Lactic Acid/blood , Double-Blind Method , Running/physiology , Adult , Physical Exertion/physiology , Physical Exertion/drug effects , Athletic Performance/physiology
18.
Med Sci Monit ; 30: e944632, 2024 Sep 21.
Article in English | MEDLINE | ID: mdl-39305004

ABSTRACT

BACKGROUND Awake endotracheal intubation (AEI) involves the placement of an endotracheal tube in patients who can maintain spontaneous respirations. This retrospective study aimed to compare sedation with remimazolam during AEI with that of dexmedetomidine in patients who underwent scoliosis correction surgery. MATERIAL AND METHODS This is a retrospective study based on data from 98 patients who had AEI procedures between January and December 2023. The remimazolam group included 55 patients, and the dexmedetomidine group included 43 patients. Remimazolam 0.05 mg/kg was injected 1 min before intubation, while dexmedetomidine 1 ug/kg was pumped 10 min before intubation. Evaluations of AEI, hemodynamics, and respiratory adverse events were then compared between the 2 groups. RESULTS There was no significant difference in demographic data between the groups. After administrating sedation, dexmedetomidine led to a larger reduction of mean arterial pressure (MAP) and heart rate (HR) than did remimazolam (11.30±1.86 vs 8.33±2.28 mmHg, P<0.001; 12.28±2.50 vs 2.85±1.82 beats/min, P<0.001). When conducting intubation, the increase of MAP in the remimazolam group was lower than that in the dexmedetomidine group (7.40±2.81 vs 9.26±5.08 mmHg, P=0.024), while the difference in HR change was not significant (7.53±5.41 vs 8.37±5.31 beats/min, P=0.441). When combined with local anesthesia, the success rate of AEI, time of AEI procedure, attempt times, increase of MAP during intubation, depth of sedation, and respiratory adverse events were comparable between the groups (P>0.05). CONCLUSIONS With local anesthesia, remimazolam and dexmedetomidine sedation can facilitate AEI for patients with scoliosis. However, remimazolam is associated with more stable hemodynamics.


Subject(s)
Dexmedetomidine , Hypnotics and Sedatives , Intubation, Intratracheal , Scoliosis , Humans , Dexmedetomidine/administration & dosage , Dexmedetomidine/pharmacology , Retrospective Studies , Scoliosis/surgery , Female , Intubation, Intratracheal/methods , Male , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/pharmacology , Wakefulness/drug effects , Adolescent , Benzodiazepines/administration & dosage , Hemodynamics/drug effects , Heart Rate/drug effects , Adult , Conscious Sedation/methods
19.
Sci Rep ; 14(1): 21628, 2024 09 16.
Article in English | MEDLINE | ID: mdl-39285220

ABSTRACT

This study aimed to investigate effects of epigallocatechin gallate (EGCG) on blood pressure (BP) and autonomic nervous system, indicated by 5-min heart rate variability (HRV) measurement in obese subjects, and determine correlations of BP with metabolic factors. In a double-blind, randomized controlled trial, obese subjects (n = 30) were randomly allocated to receive 150 mg EGCG (n = 15) or placebo (n = 15) twice a day without dietary restrictions. After 8-week EGCG treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) significantly decreased, while the low-frequency (LF) to high-frequency power (HF) ratio (LF/HF ratio) significantly increased (P < 0.05 all), indicating a shift toward sympathetic dominance, either directly or indirectly after BP lowering. SBP had positive correlations with obesity parameters, leptin, insulin, and insulin resistance but had a negative correlation with insulin sensitivity. DBP was positively correlated with age and HF in normalized unit, but negatively correlated with height and LF in ms2. High-density lipoprotein cholesterol (HDL-C) was negatively correlated with SBP, DBP, and MAP reflecting its protective effect against elevated BP. In conclusion, the 8-week EGCG treatment decreased BP and increased the LF/HF ratio, reflecting increased sympathetic activity, either a direct EGCG effect or an indirect compensatory response following BP reduction.


Subject(s)
Blood Pressure , Catechin , Heart Rate , Obesity , Humans , Catechin/analogs & derivatives , Catechin/pharmacology , Catechin/administration & dosage , Obesity/physiopathology , Obesity/drug therapy , Heart Rate/drug effects , Male , Female , Blood Pressure/drug effects , Adult , Middle Aged , Double-Blind Method , Sympathetic Nervous System/drug effects
20.
Intensive Care Med ; 50(10): 1622-1634, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39297945

ABSTRACT

PURPOSE: Excessive tachycardia in resuscitated septic shock patients can impair hemodynamics and worsen patient outcome. We investigated whether heart rate (HR) control can be achieved without increased vasopressor requirements using the titratable highly selective, ultra-short-acting ß1-blocker landiolol. METHODS: This randomized, open-label, controlled trial was conducted at 20 sites in 7 European countries from 2018 to 2022 and investigated the efficacy and safety of landiolol in adult patients with septic shock and persistent tachycardia. Patients were randomly assigned to receive either landiolol along with standard treatment (n = 99) or standard treatment alone (n = 101). The combined primary endpoint was HR response (i.e., HR within the range of 80-94 beats per minute) and its maintenance without increasing vasopressor requirements during the first 24 h after treatment start. Key secondary endpoints were 28-day mortality and adverse events. RESULTS: Out of 196 included septic shock patients, 98 received standard treatment combined with landiolol and 98 standard treatment alone. A significantly larger proportion of patients met the combined primary endpoint in the landiolol group than in the control group (39.8% [39/98] vs. 23.5% [23/98]), with a between-group difference of 16.5% (95% confidence interval [CI]: 3.4-28.8%; p = 0.013). There were no statistically significant differences between study groups in tested secondary outcomes and adverse events. CONCLUSION: The ultra-short-acting beta-blocker landiolol was effective in reducing and maintaining HR without increasing vasopressor requirements after 24 h in patients with septic shock and persistent tachycardia. There were no differences in adverse events and clinical outcomes such as 28-day mortality vs. standard of care. The results of this study, in the context of previous trials, do not support a treatment strategy of stringent HR reduction (< 95 bpm) in an unselected septic shock population with persistent tachycardia. Further investigations are needed to identify septic shock patient phenotypes that benefit clinically from HR control.


Subject(s)
Heart Rate , Morpholines , Shock, Septic , Tachycardia , Urea , Humans , Shock, Septic/drug therapy , Shock, Septic/complications , Shock, Septic/physiopathology , Male , Female , Middle Aged , Urea/analogs & derivatives , Urea/therapeutic use , Urea/pharmacology , Tachycardia/drug therapy , Tachycardia/physiopathology , Tachycardia/complications , Aged , Heart Rate/drug effects , Morpholines/therapeutic use , Morpholines/pharmacology , Europe
SELECTION OF CITATIONS
SEARCH DETAIL